Bovie Medical Corporation to Release Third Quarter of Fiscal Year 2018 Financial Results on November 1, 2018
04 10월 2018 - 5:05AM
Business Wire
Bovie Medical (NYSEMKT:BVX), a medical technology company
and the developer of J-Plasma®, a patented surgical product
marketed and sold under the Renuvion™ Cosmetic Technology brand in
the cosmetic surgery market, today announced that financial results
for the third quarter of fiscal year 2018 will be released after
the market closes on Thursday, November 1.
Management will host a conference call at 4:30 p.m. Eastern Time
on November 1 to discuss the results of the quarter and to host a
question and answer session. To listen to the call by phone,
interested parties may dial 844-507-6493 (or 647-253-8641 for
international callers) and provide access code 6375776.
Participants should ask for the Bovie Medical Corporation Call. A
live webcast of the call will be accessible via the Investor
Relations section of the Company’s website and at:
https://event.on24.com/wcc/r/1822306/45823D187A3462B4AEEA8EC718B8449B.
A telephonic replay will be available approximately two hours
after the end of the call through November 15, 2018. The replay can
be accessed by dialing 800-585-8367 for U.S. callers or
416-621-4642 for international callers and using the replay access
code: 6375776. The webcast will be archived on the Investor
Relations section of the Company’s website.
About Bovie Medical Corporation
Bovie Medical Corporation is a medical technology company and
the developer of J-Plasma® (marketed and sold under the Renuvion™
Cosmetic Technology brand in the cosmetic surgery market), a
patented plasma-based surgical product for cutting, coagulation and
ablation of soft tissue. J-Plasma technology utilizes a helium
ionization process to produce a stable, focused beam of plasma that
provides surgeons with greater precision, and minimal invasiveness.
The Company also leverages its expertise through original equipment
manufacturing (OEM) agreements with other medical device
manufacturers. For further information about the Company and its
products, please refer to the Bovie Medical Corporation website at
www.boviemedical.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181003005857/en/
Investor Relations:Westwicke Partners on behalf of Bovie
Medical CorporationMike Piccinino, CFAManaging
Director443-213-0500investor.relations@boviemed.com
Bovie (AMEX:BVX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Bovie (AMEX:BVX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Bovie Medical Corp. (아메리카 증권거래소)의 실시간 뉴스: 최근 기사 0
More Bovie Medical Corp. News Articles